Shanghai Haohai Biological Tech Co Net Assets
Shanghai Haohai Biological Tech Co net assets. Based on the latest financial reports, Shanghai Haohai Biological Tech Co (688366) has net assets worth CN¥5.88 Billion CNY (≈ $861.07 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.12 Billion ≈ $1.04 Billion USD) and total liabilities (CN¥1.23 Billion ≈ $180.52 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 688366 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.88 Billion |
| % of Total Assets | 82.67% |
| Annual Growth Rate | 25.35% |
| 5-Year Change | 3.19% |
| 10-Year Change | 121.99% |
| Growth Volatility | 94.04 |
Net Assets of Shanghai Haohai Biological Tech Co (2012–2024)
Net assets of Shanghai Haohai Biological Tech Co from 2012 to 2024. This chart illustrates how Shanghai Haohai Biological Tech Co's net assets have evolved over time, based on quarterly financial data. See 688366 net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Shanghai Haohai Biological Tech Co (2012–2024)
The table below shows the annual net assets of Shanghai Haohai Biological Tech Co from 2012 to 2024. For live market cap and overall valuation, see 688366 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.92 Billion ≈ $865.85 Million |
-1.67% |
| 2023-12-31 | CN¥6.02 Billion ≈ $880.52 Million |
+1.95% |
| 2022-12-31 | CN¥5.90 Billion ≈ $863.70 Million |
-2.61% |
| 2021-12-31 | CN¥6.06 Billion ≈ $886.81 Million |
+5.69% |
| 2020-12-31 | CN¥5.73 Billion ≈ $839.10 Million |
+1.43% |
| 2019-12-31 | CN¥5.65 Billion ≈ $827.26 Million |
+47.40% |
| 2018-12-31 | CN¥3.84 Billion ≈ $561.25 Million |
+13.92% |
| 2017-12-31 | CN¥3.37 Billion ≈ $492.65 Million |
+12.75% |
| 2016-12-31 | CN¥2.99 Billion ≈ $436.93 Million |
+12.02% |
| 2015-12-31 | CN¥2.67 Billion ≈ $390.04 Million |
+348.61% |
| 2014-12-31 | CN¥594.16 Million ≈ $86.94 Million |
+9.01% |
| 2013-12-31 | CN¥545.05 Million ≈ $79.76 Million |
+38.57% |
| 2012-12-31 | CN¥393.33 Million ≈ $57.56 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Haohai Biological Tech Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1032.7% over the analyzed period, indicating profitable operations and earnings retention.
Shanghai Haohai Biological Tech Co Net Assets Breakdown (December 2024)
Shanghai Haohai Biological Tech Co net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.86 Billion | 51.38% |
| Common Stock | CN¥233.19 Million | 4.18% |
| Other Comprehensive Income | CN¥-69.82 Million | -1.25% |
| Other Components | CN¥2.55 Billion | 45.69% |
| Total Equity | CN¥5.58 Billion | 100.00% |
Shanghai Haohai Biological Tech Co Competitors by Market Cap
The table below lists competitors of Shanghai Haohai Biological Tech Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Latigo Biotherapeutics, Inc. Common Stock
NASDAQ:LTGO
|
$835.37 Million |
|
Galaxy Surfactants Limited
NSE:GALAXYSURF
|
$835.53 Million |
|
SUFA Technology Industry Co Ltd CNNC
SHE:000777
|
$835.98 Million |
|
Changzhou Youon Pubilic Bicycle System Co Ltd
SHG:603776
|
$836.06 Million |
|
Jiangsu Sanfangxiang Industry Co Ltd
SHG:600370
|
$834.95 Million |
|
D-MARKET E.S.+T.SP.ADR/1B
F:8WZ
|
$834.81 Million |
|
Abacus Global Management, Inc.
NYSE:ABX
|
$834.17 Million |
|
KEDE Numerical Control Co Ltd
SHG:688305
|
$834.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Haohai Biological Tech Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,650,064,000 to 5,575,259,000, a change of -74,805,000 (-1.3%).
- Net income of 420,447,000 contributed positively to equity growth.
- Dividend payments of 259,859,000 reduced retained earnings.
- Share repurchases of 175,354,000 reduced equity.
- New share issuances of 49,451,000 increased equity.
- Other comprehensive income decreased equity by 87,034,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥420.45 Million | +7.54% |
| Dividends Paid | CN¥259.86 Million | -4.66% |
| Share Repurchases | CN¥175.35 Million | -3.15% |
| Share Issuances | CN¥49.45 Million | +0.89% |
| Other Comprehensive Income | CN¥-87.03 Million | -1.56% |
| Other Changes | CN¥-22.46 Million | -0.4% |
| Total Change | CN¥- | -1.32% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Haohai Biological Tech Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 9.65x to 1.25x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥3.11 | CN¥30.00 | x |
| 2013-12-31 | CN¥4.42 | CN¥30.00 | x |
| 2014-12-31 | CN¥3.71 | CN¥30.00 | x |
| 2015-12-31 | CN¥18.11 | CN¥30.00 | x |
| 2016-12-31 | CN¥18.14 | CN¥30.00 | x |
| 2017-12-31 | CN¥20.00 | CN¥30.00 | x |
| 2018-12-31 | CN¥22.57 | CN¥30.00 | x |
| 2019-12-31 | CN¥30.67 | CN¥30.00 | x |
| 2020-12-31 | CN¥31.03 | CN¥30.00 | x |
| 2021-12-31 | CN¥23.32 | CN¥30.00 | x |
| 2022-12-31 | CN¥31.78 | CN¥30.00 | x |
| 2023-12-31 | CN¥33.26 | CN¥30.00 | x |
| 2024-12-31 | CN¥23.92 | CN¥30.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Haohai Biological Tech Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.54%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.69%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.28x
- Recent ROE (7.54%) is below the historical average (12.87%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 30.56% | 37.60% | 0.68x | 1.20x | CN¥76.65 Million |
| 2013 | 26.67% | 35.28% | 0.65x | 1.17x | CN¥88.46 Million |
| 2014 | 30.90% | 35.58% | 0.69x | 1.27x | CN¥124.17 Million |
| 2015 | 10.27% | 41.19% | 0.24x | 1.06x | CN¥7.28 Million |
| 2016 | 10.50% | 35.84% | 0.23x | 1.27x | CN¥14.65 Million |
| 2017 | 11.64% | 27.69% | 0.33x | 1.27x | CN¥52.36 Million |
| 2018 | 11.48% | 26.82% | 0.35x | 1.23x | CN¥53.39 Million |
| 2019 | 6.80% | 23.24% | 0.26x | 1.13x | CN¥-174.70 Million |
| 2020 | 4.19% | 17.37% | 0.21x | 1.15x | CN¥-319.00 Million |
| 2021 | 6.16% | 20.13% | 0.25x | 1.22x | CN¥-219.11 Million |
| 2022 | 3.27% | 8.58% | 0.31x | 1.25x | CN¥-370.99 Million |
| 2023 | 7.36% | 15.79% | 0.37x | 1.26x | CN¥-148.89 Million |
| 2024 | 7.54% | 15.69% | 0.38x | 1.28x | CN¥-137.08 Million |
Industry Comparison
This section compares Shanghai Haohai Biological Tech Co's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $3,902,416,336
- Average return on equity (ROE) among peers: -1.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Haohai Biological Tech Co (688366) | CN¥5.88 Billion | 30.56% | 0.21x | $834.98 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $148.06 Million | 1.35% | 0.30x | $9.88 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $458.65 Million | 26.71% | 1.60x | $1.35 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $144.30 Million | -93.32% | 1.86x | $385.86 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $1.00 Billion | -10.32% | 0.29x | $464.02 Million |
| Chengzhi Shareholding Co Ltd (000990) | $2.62 Billion | 5.26% | 0.88x | $1.28 Billion |
| Hualan Biological EngineeringInc (002007) | $588.30 Million | 13.43% | 0.39x | $3.29 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $269.70 Million | 9.75% | 0.10x | $1.08 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $32.47 Billion | 4.86% | 0.16x | $4.77 Billion |
| Baolingbao Biology Co Ltd (002286) | $112.53 Million | 17.78% | 3.51x | $487.64 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $1.21 Billion | 14.10% | 0.09x | $1.62 Billion |
About Shanghai Haohai Biological Tech Co
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyal… Read more